Begin main content

Delta-9-tetrahydrocannabinol/Cannabidiol for Spasticity in Multiple Sclerosis: Clinical Effectiveness and Guidelines

Last updated: May 4, 2016
Project Number: RB0983-000
Product Line: Rapid Response
Research Type: Drug
Report Type: Summary of Abstracts
Result type: Report

Question

1.  What is the clinical effectiveness of delta-9-tetrahydrocannabinol/cannabidiol for the treatment of spasticity in patients with Multiple Sclerosis?

2.  What are the evidence-based guidelines associated with delta-9-tetrahydrocannabinol/cannabidiol for the treatment of spasticity in patients with Multiple Sclerosis?

Key Message

Three systematic reviews, five randomized controlled trials, and two evidence-based guidelines were identified regarding delta-9-tetrahydrocannabinol/cannabidiol for the treatment of spasticity in patients with Multiple Sclerosis.